Steris plc Stock (IE00BFY8C754): Next Earnings on February 4, 2026

Steris plc prepares for its next quarterly earnings release on Wednesday, February 4, 2026, after market close. Investors await updates on revenue, margins, and guidance from the medical device and healthcare firm.

Steris plc prepares for its next quarterly earnings release on Wednesday, February 4, 2026, after market close. The company, listed on the NYSE under ticker STE, has scheduled this event as confirmed by market data sources.

As of: Thursday, April 30, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: Steris plc
• ISIN: IE00BFY8C754
• Sector/Industry: Healthcare / Medical Devices
• Primary Exchange: NYSE (STE)
• Trading Currency: USD
• Next Earnings Date: February 4, 2026 after market close

How Steris plc Makes Money: The Core Business Model

Steris plc provides infection prevention and other surgical products and services. The company operates through segments including Healthcare, Applied Sterilization Technologies, and Life Sciences. These segments generate revenue from equipment sales, consumables, and service contracts in healthcare facilities worldwide.

The Healthcare segment offers sterilizer systems, washing systems, and surgical tables. Revenue comes from initial equipment sales followed by recurring consumables and maintenance services. This model supports steady cash flow as hospitals require ongoing sterilization solutions.

Applied Sterilization Technologies provides contract sterilization and lab services to medical device manufacturers. Life Sciences focuses on sterility assurance products for pharmaceutical production. These diversified operations reduce reliance on any single market.

Steris plc's Key Revenue and Product Drivers

In the last 12 months, Steris plc reported revenue of $5.70 billion. Profits reached $688.44 million with earnings per share of $6.97, according to market data as of recent updates.

Gross margin stood at 44.51%, operating margin at 18.64%, and profit margin at 12.07% over the same period. These figures reflect efficiency in production and service delivery for sterilization products.

Key products include the V-PRO sterilizers and Harmony sterilizing and drying systems. Consumables like sterilization wraps and indicators drive recurring revenue. Services such as preventive maintenance contracts contribute to long-term customer relationships.

Industry Trends and Competitive Landscape

The medical device sterilization market grows with rising demand for outpatient procedures and hospital capacity expansions. Regulatory standards from FDA and EPA mandate advanced sterilization technologies.

Steris plc competes with firms like Fortive Corporation in instrument cleaning and STERIS-focused niches. Peers operate in overlapping segments of healthcare equipment and services.

Trends include adoption of low-temperature sterilization for heat-sensitive devices and integration of digital monitoring in sterilization processes. These shifts favor established players with comprehensive portfolios.

Why Steris plc Matters to US Investors

Steris plc trades on the NYSE as STE in USD, providing direct access for US investors. The company files SEC reports, ensuring transparency under US regulatory standards.

Major revenue derives from US healthcare providers, tying performance to domestic hospital spending and procedure volumes. NYSE listing facilitates institutional ownership by US funds.

USD trading eliminates direct FX risk for American portfolios. Exposure to US medical device demand aligns with sector growth from elective surgeries and infection control priorities.

Which Investor Profile Fits Steris plc – and Which Does Not?

Investors focused on healthcare equipment with recurring revenue streams may track Steris plc. Profiles seeking stability from service contracts and consumables find alignment.

Those preferring high-growth tech or cyclical commodities may look elsewhere. Steris plc suits portfolios emphasizing defensive healthcare subsectors.

Long-term holders interested in regulatory moats in sterilization benefit from industry barriers. Short-term traders chasing volatility in unrelated sectors mismatch.

Risks and Open Questions for Steris plc

Supply chain disruptions in medical components pose risks to production timelines. Regulatory changes in sterilization standards require ongoing compliance investments.

Hospital budget constraints from reimbursement pressures impact equipment purchases. Competition in contract sterilization services pressures margins.

Macroeconomic factors like inflation affect input costs for manufacturing. Acquisition integration challenges arise from past deals in the sector.

Key Events and Outlook for Investors

The confirmed earnings date of February 4, 2026, after market close sets the near-term focus. Updates on quarterly performance and guidance will inform expectations.

Investors monitor progress in product launches and service expansions ahead of the report.

What to Watch Next

• February 4, 2026: Quarterly earnings after market close

Conclusion

Steris plc approaches its next earnings on February 4, 2026, after market close, a key event for tracking progress in healthcare and sterilization segments. Recent 12-month revenue of $5.70 billion and margins reflect operational scale. US investors benefit from NYSE listing and SEC oversight. The scheduled release provides concrete visibility into near-term developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.